Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin
Status: Recruiting
Location: See all (7) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant.
• Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires.
• Age ≥ 18 years at the time of consent.
• ECOG Performance Status of ≤ 3 within 28 days prior to consent.
• Histological or cytologically confirmed urothelial carcinoma.
• Patients must be planned to start systemic therapy with enfortumab vedotin
• At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab
Locations
United States
New Jersey
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)
RECRUITING
Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING
Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING
Montvale
New York
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
RECRUITING
Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING
Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
RECRUITING
New York
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
RECRUITING
Rockville Centre
Contact Information
Primary
Samuel Funt, MD
funts@mskcc.org
646-888-4770
Backup
Gopakumar Iyer, MD
646-888-4717
Time Frame
Start Date:2026-01-20
Estimated Completion Date:2028-01-20
Participants
Target number of participants:50
Treatments
Participants With Urothelial Carcinoma
Participants will have histological or cytologically confirmed urothelial carcinoma